Medscape

Novel Med Tied to Slowed Decline in Lewy Body Dementia

The experimental drug neflamapimod reduced a key biomarker of neurodegeneration, which correlated with a slowing of cognitive ...
Le Lézard

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

Pfizer Inc. today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment ...
BMJ Open

Exploring a panel of serum biomarkers for cancer risk in patients with non-specific symptoms: a comparative analysis of feature selection methods

Objectives Delays in cancer diagnosis for patients with non-specific symptoms (NSSs) lead to poorer outcomes. Rapid ...
Le Lézard

CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood ...